Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14348MR)

This product GTTS-WQ14348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14348MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14309MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ765MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ12937MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ3799MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ9437MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ13850MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ8660MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ9899MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW